THE DOWNSIDE IS ANDRE UDDIN ONLY VALUES AGN @ 25 CENT CAD PER SHARE. THAT'S WITH UDDIN INCLUDING THE PENDING DATA READOUT FOR IPF/CC AND THE PHASE 1 DMT STUDY. THUS FAR ANDRE UDDIN IS THE ONLY PERSON COVERING THIS JUNK STOCK AND HE'S THUS FAR BEEN CORRECT IN HIS PREDICTIONS. HE NAILED IT WITH THE FINAL DATA READOUT FOR COVID-19 AND TOLD THE ENTIRE MARKET BACK ON APRIL FOOLS' DAY (APRIL 1 2021):
“Ifenprodil is in a Phase 2a trial in IPF/chronic cough where results are expected in H2 2021, and AGN’s DMT (a repurposed psychedelic compound) is expected to enter into a Phase 1 trial in stroke in H2 2021,” Uddin wrote. “Investors should re-focus their attention towards the IPF/cough data expected in H2 ’21.”
“Investors should note our AGN valuation is based on the IPF and chronic cough indications of ifenprodil – we are currently keeping our financial assumptions for the two indications intact in our model. We never assumed any revenues from ifenprodil’s COVID-19 indication,” he said.
Along with the new “Hold” rating, Uddin has cut his price target from $0.80 to $0.25, saying the drop is due to a decrease in assumed success rate for Ifenprodil. At the time of publication, the new target represented a projected one-year return of negative 15 per cent.
Take a pass on Algernon Pharmaceuticals, says Mackie - Cantech Letter
ANDRE UDDIN HAS TAKEN INTO ACCOUNT THE UPCOMING DATA READOUT FOR IPF?CC, THE PENDING PHASE 1 STUDY FOR PHASE 1 DMT IN Q4 2021, AND THE PHASE 1 STUDY FOR PANCREATIC CANCER SOMETIME IN 2022. NOTING THAT AT THE TIME OF UDDIN’S BLISTERING ANALYSIS OF AGN - THE TARGETED START DATE FOR PHASE 1 DMT WAS Q2 2021 AND THE TARGETED DATA READOUT FOR IPF/CC WAS Q2 2021 (LAST QUARTER). THE TIMELINE FOR IPF/CC REMAINS THE BIGGEST BLUNDER OF ALL. IT’S KILLED MOMENTUM AND MORE IMPORTANTLY IT”S KILLED THE COMPANIES CREDIBILITY WITH THE JUNK STOCK MARKET - IF SUCH CREDIBILITY EVER EXISTED. THE MARKET CONTINUES TO AWAIT A 20 PERSON DATA READOUT FOR IPF/CC AND THE KICKER IN THE @SS IS IT”S STILL ONLY A PHASE 2a STUDY. WHICH MEANS IF THERE’S ANY POSITIVE DATA THE COMPANY IS SIMPLY GOING TO ROLL OUT YET ANOTHER PHASE 2 STUDY FOR IPF AND/OR CHRONIC COUGH. GETTING TO PHASE 3 HAS BECOME A DAUNTING CHALLENGE FOR A COMPANY THAT TOUTS SPEEDINESS FOR IT’S SO-CALLED ABILITY TO ENTER CLINICAL TRIALS AT PHASE 2 VERSUS STARTING FROM SCRATCH AT PHASE 1. YET, THAT SUPPOSED ADVANTAGE DOESN’T APPLY TO THE NEXT TWO STUDIES (DMT/PANCREATIC CANCER) COMING FORTH AT SOME POINT IN THE FUTURE. THE ENTIRE REPURPOSED DRUGS STRATEGY HAS BEEN TURNED ON ITS HEAD BY MANAGEMENT/BOARD OF DIRECTORS AND THERE REMAINS NO SIGHT OF DRY LAND ON THE ALGERNON SHIP THAT SUNK TO NEARLY ROCK BOTTOM.
WE SEEK SAFE HARBOR,
COMMON SHAREHOLDERS